Indian CRO Kreara Solutions Pvt Ltd. Joins DATATRAK CRO Connect Program

Indian CRO Kreara Solutions Pvt Ltd. Joins DATATRAK CRO Connect Program
CLEVELAND, March 8 /PRNewswire-FirstCall/ -- DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced that Kreara Solutions Pvt Ltd. has become the latest Contract Research Organization (CRO) to join the global list of DATATRAK CRO Connect partners. Through the adoption of DATATRAK ONETM, Kreara will be able to deliver superior client service while managing its supported studies through the versatile DATATRAK eClinicalTM platform. Interestingly, Kreara is also collaborating with PFC Pharma Focus, a CRO with corporate offices in Europe and Israel, which joined the DATATRAK CRO Connect Program in November 2009.

"We have been on the lookout for a cost effective and quality solution to provide EDC solutions to our clinical data management customers for quite some time," said Anoop P Ambika, Chairman and Managing Director of Kreara Solutions. "While we evaluated several products that are currently being offered by the market, we found the right mix of cost, quality and professional support with DATATRAK. We are pleased to be listed as one of the very few providers from India who has entered the CRO connect program. We are also quite confident that we will be able to deliver value to our customers through this new partnership."

"We are pleased to see our network of CRO Connect Partners extend into India," said Laurence Birch, DATATRAK's Chairman of the Board. "With almost a half-dozen studies already underway in India, we expect to see a tremendous amount of growth for DATATRAK eClinicalTM in the Indian market over the next several years. I would like to welcome Kreara to the family of DATATRAK CRO Connect Partners, and we look forward to working with Kreara in future".

About Kreara.

Kreara was established in India in April 2004 as a private limited company with the intention of providing quality data management and bio-statistical services for the clinical research and life sciences industry. Ever since our inception we have grown into one of the most trusted partner for pharmaceutical companies across the globe. The company employs a good mix of statisticians, software engineers and clinical data managers and specializes in Clinical Data Management, Biostatistics, SAS programming, Medical coding, safety and efficacy analysis, medical writing and CDISC migration. In the course of our existence over the past five years, we have worked with clients from Europe, USA and Japan. We have also developed a state of the art training program that provides us with industry ready resources. At Kreara our primary job function is to create value for our customers. An integral part of our genetic structure is to create long-lasting customer partnerships and working with our customers to identify their needs and provide solutions that support their success.  We have a successful track record of treating each of our customers from the life sciences industry with respect and providing them with three value additions; Cost Effectiveness, Quality and Timeliness.  For more information on Kreara, please visit http://www.kreara.com.

About DATATRAK International, Inc.

DATATRAK International, Inc. is a worldwide technology and services company focused on the provision of multi-component eClinical solutions and related services for the clinical trials industry. We operate under the vision of DATATRAK ONETM, which encompasses our unique, single platform technology. The singular architecture of our DATATRAK eClinicalTM product suite has been embraced by clients around the globe for its ability to effectively manage clinical trials through a unified multi-component, comprehensive solution. The Company delivers a complete portfolio of software products that were created in order to accelerate clinical research data from investigative sites to clinical trial sponsors and ultimately the FDA, faster and more efficiently than manual methods or loosely integrated technologies. DATATRAK's eClinicalTM software suite can be deployed worldwide through an ASP offering or in a licensed Enterprise Transfer model that fully empowers its clients. The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 16 drugs and one medical device that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio, and Bryan, Texas. Visit the DATATRAK International, Inc. web site at www.datatrak.net.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors (including those specified below) which are difficult to predict and, in many instances, are beyond the control of the Company. Factors that may cause actual results to differ materially from those in the forward-looking statements include the limited operating history on which the Company's performance can be evaluated; the ability of the Company to continue to enhance its software products to meet customer and market needs; fluctuations in the Company's quarterly results; the viability of the Company's business strategy and its early stage of development; the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; the Company's dependence on major customers; government regulation associated with clinical trials and the approval of new drugs; the ability of the Company to compete in the emerging EDC market; losses that potentially could be incurred from breaches of contracts or loss of customer data; the inability to protect intellectual property rights or the infringement upon other's intellectual property rights; the costs associated with maintaining and/or developing two product suites; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets. This list of factors is not all-inclusive. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.


SOURCE DATATRAK International, Inc.

Back to top
RELATED LINKS
http://www.datatrak.net

Suggested Articles

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.

Broad Institute researchers showed that base-editing the Tmc1 gene preserved hair cells that helped transmit sound in the ears of mice.

Five Prime Therapeutics’ clinical development lead is hoping for a more stable time at new employer Spectrum Pharma.